New drug could help patients with painful muscle disease ditch steroids
NCT ID NCT03632187
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This phase 3 trial tested whether abatacept, a drug that calms the immune system, can control polymyalgia rheumatica (a painful inflammatory condition) without the need for long-term steroids. Thirty-four adults with early disease received either abatacept or a placebo for 12 weeks. The goal was to see if more patients could achieve low disease activity without steroids. The study is complete, and results will show if abatacept is a safer alternative to standard steroid treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Le Mans
Le Mans, France
-
CH St-Malo
St-Malo, France
-
CH de Morlaix
Morlaix, France
-
CHRU de Brest
Brest, France, 29609, France
-
CHU Strasbourg
Strasbourg, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abatacept (a drug that calms the immune system)
What this could lead to
If it works, this could offer a way to control polymyalgia rheumatica with less reliance on steroids, reducing side effects.
What could go wrong
This is a small, early-phase trial with only 34 participants. The drug may not work better than placebo, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.